Best practices in diagnostic immunohistochemistry: myoepithelial markers in breast pathology

R Dewar, O Fadare, H Gilmore… - Archives of pathology …, 2011 - meridian.allenpress.com
Context.—Numerous immunohistochemical stains have been shown to exhibit exclusive or
preferential positivity in breast myoepithelial cells relative to their luminal/epithelial …

[HTML][HTML] Hydrogen sulfide and its donors: Novel antitumor and antimetastatic therapies for triple-negative breast cancer

H Li, F Xu, G Gao, X Gao, B Wu, C Zheng, P Wang, Z Li… - Redox biology, 2020 - Elsevier
Hydrogen sulfide (H 2 S) is considered as a novel second-messenger molecule associated
with the modulation of various physiological and pathological processes. In the field of …

Systemic delivery of anti-miRNA for suppression of triple negative breast cancer utilizing RNA nanotechnology

D Shu, H Li, Y Shu, G Xiong, WE Carson III, F Haque… - ACS …, 2015 - ACS Publications
MicroRNAs play important roles in regulating the gene expression and life cycle of cancer
cells. In particular, miR-21, an oncogenic miRNA is a major player involved in tumor …

[HTML][HTML] Wnt/β-catenin pathway activation is enriched in basal-like breast cancers and predicts poor outcome

AI Khramtsov, GF Khramtsova, M Tretiakova… - The American journal of …, 2010 - Elsevier
Although Wnt/β-catenin pathway activation has been implicated in mouse models of breast
cancer, there is contradictory evidence regarding its importance in human breast cancer. In …

Delivery of anti-miRNA for triple-negative breast cancer therapy using RNA nanoparticles targeting stem cell marker CD133

H Yin, G Xiong, S Guo, C Xu, R Xu, P Guo, D Shu - Molecular Therapy, 2019 - cell.com
Triple-negative breast cancer (TNBC) is an aggressive disease with a short median time
from relapse to death. The increased aggressiveness, drug resistance, disease relapse, and …

Glycoprotein nonmetastatic B is an independent prognostic indicator of recurrence and a novel therapeutic target in breast cancer

AAN Rose, AA Grosset, Z Dong, C Russo… - Clinical cancer …, 2010 - AACR
Purpose: Although the murine orthologue of glycoprotein nonmetastatic B (GPNMB),
Osteoactivin, promotes breast cancer metastasis in an in vivo mouse model, its importance …

Frequent PTEN genomic alterations and activated phosphatidylinositol 3-kinase pathway in basal-like breast cancer cells

B Marty, V Maire, E Gravier, G Rigaill… - Breast Cancer …, 2008 - Springer
Abstract Introduction Basal-like carcinomas (BLCs) and human epidermal growth factor
receptor 2 overexpressing (HER2+) carcinomas are the subgroups of breast cancers that …

Basal-like breast cancer: molecular profiles, clinical features and survival outcomes

HH Milioli, I Tishchenko, C Riveros, R Berretta… - BMC medical …, 2017 - Springer
Background Basal-like constitutes an important molecular subtype of breast cancer
characterised by an aggressive behaviour and a limited therapy response. The outcome of …

TTK/hMPS1 is an attractive therapeutic target for triple-negative breast cancer

V Maire, C Baldeyron, M Richardson, B Tesson… - PloS one, 2013 - journals.plos.org
Triple-negative breast cancer (TNBC) represents a subgroup of breast cancers (BC)
associated with the most aggressive clinical behavior. No targeted therapy is currently …

Breast cancer subtypes: morphologic and biologic characterization

S Masood - Women's Health, 2016 - journals.sagepub.com
Advances in basic science, technology and translational research have created a revolution
in breast cancer diagnosis and therapy. Researchers' discoveries of genes defining …